Curcumin (Synonyms: 姜黃素; Diferuloylmethane; Natural Yellow 3; Turmeric yellow)

目錄號(hào): HY-N0005 純度: 98.16%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Curcumin (Diferuloylmethane)，是一種天然酚類化合物，是乙酰轉(zhuǎn)移酶 p300/CREB 結(jié)合蛋白 特異性抑制劑，抑制組蛋白/非組蛋白的乙?；徒M蛋白乙酰轉(zhuǎn)移酶依賴的染色質(zhì)轉(zhuǎn)錄。Curcumin 對(duì) NF-κb 和 MAPKs 有抑制作用，并具有抗炎、抗氧化、抗增殖和抗血管生成等多種藥理作用。Curcumin 通過(guò) Keap1 半胱氨酸修飾誘導(dǎo) Nrf2 蛋白的穩(wěn)定。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Curcumin Chemical Structure

CAS No. : 458-37-7

1. 客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥500	In-stock
100 mg	￥450	In-stock
500 mg	￥650	In-stock
1 g		詢價(jià)
5 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Curcumin:

Curcumin-d₆ In-stock
Curcumin (Standard) 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 79 篇科研文獻(xiàn)

•Nat Cell Biol. 2021 Jan;23(1):40-48. [Abstract]
•Chem Eng J. 2023 Sep 15, 472, 144901.
•Sci Adv. 2024 Jul 5;10(27):eado9120. [Abstract]
•J Control Release. J Control Release [Abstract]
•Theranostics. 2022 Jan 1;12(2):976-998. [Abstract]
•Sci Adv. 2020 Jul 22;6(30):eaba2987. [Abstract]

•J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]
•Int J Biol Macromol. 2023 Nov 17:128235. [Abstract]
•Acta Pharmacol Sin. 2021 Apr 13. [Abstract]
•Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
•J Med Chem. 2023 Mar 6. [Abstract]
•Br J Pharmacol. 2023 Feb 14. [Abstract]
•Phytomedicine. 2022: 154563.
•Biomed Pharmacother. 2022 May 10;151:113092. [Abstract]
•Ecotoxicol Environ Saf. 2021 Dec 21;229:113097. [Abstract]
•Phytomedicine. 14 August 2021, 153706.
•Ecotoxicol Environ Saf. 2021 Jul 19;222:112529. [Abstract]
•Oncogene. 2021 Apr;40(15):2711-2724. [Abstract]
•Bioresour Bioprocess. 2024 Nov 27;11(1):108. [Abstract]
•Mol Med. 2024 Sep 28;30(1):166. [Abstract]
•Int Immunopharmacol. 2024 Oct 2;143(Pt 1):113299. [Abstract]
•Int J Mol Sci. 2024 Aug 24.
•Int Immunopharmacol. 2024 Sep 2;142(Pt A):112953. [Abstract]
•Int J Mol Sci. 2024 Jun 18;25(12):6694. [Abstract]
•Antimicrob Agents Chemother. 2024 May 29:e0016824. [Abstract]
•Nanomaterials. 2024 Feb 20, 14(5), 389.
•Int J Mol Sci. 2023 Dec 21, 25(1), 168.
•Antioxidants (Basel). 2023 Aug 9, 12(8), 1584.
•J Enzyme Inhib Med Chem. 2023 Dec;38(1):2205052. [Abstract]
•J Ethnopharmacol. 2023 May 26;116690. [Abstract]
•J Ethnopharmacol. 2023 Apr 6;305:116051. [Abstract]
•Int J Oncol. 2023, 62(1): 1-13
•FASEB J. 2022 Nov;36(11):e22593. [Abstract]
•Fish Shellfish Immunol. 2022 Oct 4;S1050-4648(22)00640-4. [Abstract]
•Aquaculture. 15 January 2023, 738870.
•Foods. 2022 Mar 11;11(6):808. [Abstract]
•Viruses. 2022 Apr 21;14(5):861. [Abstract]
•J Cell Mol Med. 2021 Sep 16. [Abstract]
•Aging (Albany NY). 2021 Jul 29;13(14):18757-18768. [Abstract]
•Infect Dis Ther. 2021 Feb 2;1-12. [Abstract]
•FASEB J. 2021 Feb;35(2):e21316. [Abstract]
•Eur J Immunol. 2020 Sep;50(9):1350-1361. [Abstract]
•Int J Mol Sci. 2019 Jan; 20(1): 28. [Abstract]
•Drug Des Devel Ther. 2018 Dec 3;12:4095-4105. [Abstract]
•FASEB J. 2017 Sep;31(9):3800-3815. [Abstract]
•Theriogenology. 2025 Jan 15.
•Cell Div. 2024 Nov 28;19(1):33. [Abstract]
•J Cancer Res Clin Oncol. 2024 Sep 23;150(9):429. [Abstract]
•Biochem Biophys Res Commun. 2024 Oct 22:736:150871. [Abstract]
•Tissue Cell. 2024 Oct 19:91:102587. [Abstract]
•Anticancer Drugs. 2024 Sep 13. [Abstract]
•SAR QSAR Environ Res. 2024 May 24:1-24. [Abstract]
•Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov 8. [Abstract]
•J Cosmet Dermatol. 2023 Jul 3. [Abstract]
•Physiol Res. 2023 Jun.
•Mol Med Rep. 2023 Jan;27(1):17. [Abstract]
•Exp Eye Res. 2022 Sep 5;224:109239. [Abstract]
•Food Agr Immunol. 28 Aug 2022.
•Exp Ther Med. February 9, 2022.
•Toxicol Res (Camb). 18 October 2021.
•Vet Microbiol. 2021 Aug;259:109152. [Abstract]
•Virology. 2021 May 22.
•Am J Transl Res. 2021 Mar 15;13(3):1337-1351. [Abstract]
•Technol Cancer Res Treat. Jan-Dec 2020;19:1533033820962114. [Abstract]
•Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
•Cancer Biomark. 2020;29(1):1-8. [Abstract]
•Mol Cell Probes. 2020 Jun;51:101534. [Abstract]
•Exp Cell Res. 2020 Mar 15;388(2):111876. [Abstract]
•Onco Targets Ther. 2019 May 17;12:3893-3903. [Abstract]
•Mol Med Rep. 2019 Feb;19(2):1040-1048. [Abstract]
•J Cell Biochem. 2019 Apr;120(4):6718-6728. [Abstract]
•JMIR Res Protoc. 2023 Jul 28;12:e42964. [Abstract]
•Medicine. 2022 Oct 7;101(40):e30967. [Abstract]
•Rev Bras Farmacogn. 13 September 2022.
•Eur J Inflamm. December 1, 2021.
•Gastroent Res Pract. 01 Jul 2021.
•SSRN. 2024 Jun 02.
•Research Square Preprint. 2023 May 4.
•Oxid Med Cell Longev. 2023 Feb 17.

Cell Viability Assay

: Curcumin purchased from MCE. Usage Cited in: Research Square Preprint. 2023 May 4.; Curcumin (5, 10, 20, 40, 50 μM; 24 h) inhibits the viability of Hs578T cells in a concentration-dependent manner.

: Curcumin purchased from MCE. Usage Cited in: Research Square Preprint. 2023 May 4.; Curcumin (20 μM; 24 h) significantly inhibits the protein expression of Fibronectin, mTOR, β-Catenin, p-Akt, Akt, N-Cadherin, p-S6, and S6 in Hs578T cells.

: Curcumin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

: Curcumin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375, A2058, and RPMI-7951 cells were treated with DMSO (control), Curcumin (25 μM), or Apigenin (30 μM) for 24 h. Apigenin and Curcumin induce apoptosis in melanoma cells.

: Curcumin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; The protein expression levels of cleaved PARP are detected from Curcumin and Apigenin-treated A375, A2058, and RPMI-7951 cell lysates compared to control samples using Western blotting analyses.

: Curcumin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; Western analysis of PD-L1 expression in A375, A2058, and RPMI-7951 cells treated with IFN-γ, curcumin, or apigenin.

: Curcumin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

: Curcumin purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2018 Oct 29;37(1):261. [Abstract]; A375 cells are incubated with DMSO, curcumin (25 μM), or apigenin (30 μM) for 4 h and then treated with IFN-γ (10 ng/mL) for indicated times. The levels of STAT1 phosphorylation at Tyr701 and total STAT1 are detected by Western blot analysis.

: Curcumin purchased from MCE. Usage Cited in: J Cell Biochem. 2019 Apr;120(4):6718-6728. [Abstract]; Western analysis of the expression of NLRP3, pro-casp-1, casp-1, pro-1β, IL-1β in the treatment with or without Curcumin, DMSO, MSU and Colchicine.

: Curcumin purchased from MCE. Usage Cited in: FASEB J. 2017 Sep;31(9):3800-3815. [Abstract]; Expression of CFTR after treatment with Curcumin (10 μM) for 3 d is assayed by Western blotting. TDSCs from WT mice are treated with Curcumin (10 μM) for 3 d and results show that CFTR expression is increased at the protein level.

Curcumin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Histone Acetyltransferase 亞型特異性產(chǎn)品:

查看所有亞型

CBP/p300 GCN5/PCAF TIP60 MOZ/MORF HBO1

生物活性
實(shí)驗(yàn)參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.

IC₅₀ & Target

CBP/p300

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
4T1	IC₅₀	49.4 μM Compound: Curcumin	Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against mouse 4T1 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
A-431	IC₅₀	> 100 μM Compound: CUR	Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	> 10 μM Compound: Curcumin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 29886021]
A549	IC₅₀	0.2 μM Compound: 19	Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 in ILbeta-stimulated human A549 cells using PGH2 as substrate preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	10.1039/C5MD00278H
A549	IC₅₀	0.22 μM Compound: 4	Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 preincubated for 15 mins by HPLC analysis Inhibition of mPGES-1 in human IL-1beta-stimulated A549 cell microsomes assessed as reduction of PGE2 formation from PGH2 preincubated for 15 mins by HPLC analysis	[PMID: 26588603]
A549	IC₅₀	15.06 μM Compound: Curcumin	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 27816267]
A549	IC₅₀	17.3 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24280069]
A549	IC₅₀	17.9 μM Compound: Curcumin	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 30138803]
A549	IC₅₀	18 μM Compound: Curc	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
A549	IC₅₀	23.54 μM Compound: Curcumin	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 26873414]
A549	IC₅₀	24.18 μM Compound: 4	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
A549	IC₅₀	25.33 μM Compound: 1; CUR	Cytotoxicity against human A549 Cells by MTT assay Cytotoxicity against human A549 Cells by MTT assay	[PMID: 31129455]
A549	IC₅₀	27.8 μM Compound: CUR	Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
A549	IC₅₀	28 μM Compound: 1; CUR	Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay Cytotoxicity against human A549 Cells after 24 to 48 hrs by MTT assay	[PMID: 31129455]
A549	IC₅₀	32.5 μM Compound: 22	Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 32172081]
A549	IC₅₀	38.12 μM Compound: 2	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 26891099]
A549	IC₅₀	40.56 μM Compound: 2	Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549 cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
A549	IC₅₀	43.9 μM Compound: CUR	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	52.3 μM Compound: 1; CUR	Cytotoxicity against human A549 Cells after 24 hrs by MTT assay Cytotoxicity against human A549 Cells after 24 hrs by MTT assay	[PMID: 31129455]
A549	IC₅₀	6.8 μM Compound: Curcumin	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
A549	IC₅₀	60.2 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human A549 cells after 24 hrs by MTT assay Cytotoxicity against human A549 cells after 24 hrs by MTT assay	[PMID: 26174555]
A549/CDDP	IC₅₀	32.39 μM Compound: 2	Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay Antiproliferative activity against human A549/CDDP cells after 72 hrs by MTT assay	[PMID: 26891099]
A549/CDDP	IC₅₀	39.42 μM Compound: 2	Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry Inhibition of thioredoxin reductase in human A549/CDDP cells by DTNB dye based microplate spectrophotometry	[PMID: 26891099]
AGS	IC₅₀	20.76 μM Compound: 1; CUR	Cytotoxicity against human AGS Cells by MTT assay Cytotoxicity against human AGS Cells by MTT assay	[PMID: 31129455]
BGC-823	IC₅₀	> 20 μM Compound: 1; CUR	Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay Antiproliferative activity against human BGC823 cells after 24 hrs by MTT assay	[PMID: 31129455]
BGC-823	IC₅₀	19.5 μM Compound: Curcumin	Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human BGC823 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
Bone marrow cell	IC₅₀	7.5 μM Compound: Curcumin	Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay Inhibition of RANKL-induced osteoclast differentiation in ICR mouse bone marrow cells after 48 hrs by TRAP assay	[PMID: 26923696]
BT-474	IC₅₀	30.14 μM Compound: Curcumin	Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay Antiproliferative activity against HER2 positive human BT474 cells after 24 hrs by MTT assay	[PMID: 28319780]
BT-549	IC₅₀	24.93 μM Compound: Curcumin	Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay	[PMID: 28038323]
BV-2	IC₅₀	0.5 μM Compound: Curcumin	Inhibition of NO production in LPS-stimulated mouse BV-2 cells preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay Inhibition of NO production in LPS-stimulated mouse BV-2 cells preincubated with compound for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess reagent-based assay	[PMID: 33454546]
BV-2	IC₅₀	0.5 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse BV-2 cells by MTT assay Inhibition of LPS-induced NO production in mouse BV-2 cells by MTT assay	[PMID: 33454546]
BV-2	IC₅₀	0.52 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method Inhibition of LPS-induced NO production in mouse BV2 cells assessed as reduction in nitrite level pretreated for 24 hrs before LPS treatment for additional 24 hrs by Griess reaction method	[PMID: 26859776]
BV-2	IC₅₀	1.42 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 1 hr before LPS stimulation measured after 24 hrs by Griess assay	[PMID: 27592135]
BV-2	IC₅₀	2.2 μM Compound: Curcumin	Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay Inhibition of Src in mouse BV2 cells assessed as suppression of LPS-induced NO release preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay	[PMID: 27617803]
BV-2	IC₅₀	2.36 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 24 hrs followed by LPS-stimulation after 24 hrs by Griess assay	[PMID: 28032759]
BV-2	IC₅₀	2.69 μM Compound: Curcumin	Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced nitric oxide production by colorimetric assay Antiinflammatory activity in mouse BV2 cells assessed as reduction in LPS-induced nitric oxide production by colorimetric assay	[PMID: 36346918]
BV-2	IC₅₀	3 μM Compound: Curcumin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO-production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by microplate reader based colorimetric assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO-production preincubated for 1 hr followed by LPS stimulation and measured after 24 hrs by microplate reader based colorimetric assay	[PMID: 34185528]
BV-2	IC₅₀	4 μM Compound: Curcumin	Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Antiinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 29035525]
BV-2	IC₅₀	4.5 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay Inhibition of LPS-induced nitric oxide production in mouse BV2 cells pretreated for 30 mins followed by LPS-stimulation after 24 hrs by Griess assay	[PMID: 28055210]
BV-2	IC₅₀	4.77 μM Compound: Curcumin	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27228227]
BV-2	IC₅₀	6 μM Compound: Curcumin	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 15 mins followed by LPS-stimulation measured after 24 hrs by colorimetric method	[PMID: 28514148]
BXPC-3	IC₅₀	29 μM Compound: Curc	Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
Caco-2	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of undifferentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of undifferentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
Caco-2	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of differentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of differentiated human Caco2 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
Caco-2	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of undifferentiated human Caco2 cells measured after 72 hrs by SRB assay Growth inhibition of undifferentiated human Caco2 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
Caco-2	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of differentiated human Caco2 cells measured after 72 hrs by SRB assay Growth inhibition of differentiated human Caco2 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
Caco-2	IC₅₀	28 μM Compound: 1; CUR	Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay Cytotoxicity against human Caco2 Cells after 72 hrs by MTT assay	[PMID: 31129455]
Caco-2	IC₅₀	38.3 μM Compound: 1a	Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human Caco2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CCD-18Co	GI₅₀	7.2 μg/mL Compound: Curc	Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent cell viability Cytotoxicity against human CCD-18Co cells assessed as reduction in cell viability incubated for 72 hrs by CellTiter-Glo luminescent cell viability	[PMID: 31767266]
CCD-841CoN	GI₅₀	58.6 μM Compound: 5	Cytotoxicity against human CRL1790 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B assay Cytotoxicity against human CRL1790 cells assessed as reduction in cell viability after 48 hrs by sulforhodamine B assay	[PMID: 28716495]
CHO-K1	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of CHOK1 cells measured after 72 hrs by SRB assay Growth inhibition of CHOK1 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
CHO-K1	IC₅₀	21.3 μM Compound: 1; CUR	Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay Cytotoxicity against human CHOK1 Cells after 72 hrs by MTT assay	[PMID: 31129455]
CHO-K1	IC₅₀	42 μM Compound: 1a	Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
CHO-K1	IC₅₀	7.5 μM Compound: 1a	Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of CHOK1 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
COLO 201	IC₅₀	18 μM Compound: Curc	Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
COLO 205	GI₅₀	12.7 μg/mL Compound: Curc	Growth inhibition of human COLO205 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability Growth inhibition of human COLO205 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability	[PMID: 31767266]
Colon 26	IC₅₀	30.34 μM Compound: CU	Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay Cytotoxicity against mouse Colon 26 cells after 4 hrs by MTT assay	[PMID: 31336310]
CT26	IC₅₀	7.7 μM Compound: CUR	Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against mouse CT26 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
CWR22R	GI₅₀	14.3 μg/mL Compound: Curc	Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay Growth inhibition of human 22Rv1 cells incubated for 48 hrs by MTS assay	[PMID: 31767266]
DLD-1	IC₅₀	> 40 μM Compound: CUR	Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
DU-145	IC₅₀	26.23 μM Compound: 1	Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against androgen-insensitive human DU145 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 30121214]
DU-145	IC₅₀	26.23 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human DU145 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
DU-145	IC₅₀	26.23 μM Compound: 1	Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells after 3 days by WST-1 assay	[PMID: 28388523]
DU-145	IC₅₀	26.23 μM Compound: 1a; Curcumin	Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human DU145 cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
DU-145	IC₅₀	26.23 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay Antiproliferative activity against human DU145 cells after 3 days by WST or trypan blue assay	[PMID: 27543391]
DU-145	IC₅₀	28.41 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 28038323]
DU-145	IC₅₀	33.12 μM Compound: Curcumin	Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
DU-145	IC₅₀	33.15 μM Compound: Curcumin	Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29429834]
DU-145	IC₅₀	41 μM Compound: Curcumin	Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human DU145 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
DU-145	IC₅₀	44.71 μM Compound: Curcumin	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 27816267]
EA.hy 926	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of human EAhy926 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of human EAhy926 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
EA.hy 926	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of human EAhy926 cells measured after 72 hrs by SRB assay Growth inhibition of human EAhy926 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
EA.hy 926	IC₅₀	20 μM Compound: 1; CUR	Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay Cytotoxicity against human EAhy926 Cells after 72 hrs by MTT assay	[PMID: 31129455]
EA.hy 926	IC₅₀	24.6 μM Compound: 1a	Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human EAhy926 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
GES1	IC₅₀	27.89 μM Compound: CUR	Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human GES-1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
HCT-116	IC₅₀	10 μM Compound: Curcumin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr Inhibition of chymotrypsin-like activity of human 26S proteasome in human HCT-116 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometr	[PMID: 30776692]
HCT-116	IC₅₀	10.5 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 31326241]
HCT-116	IC₅₀	10.91 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 29886021]
HCT-116	IC₅₀	13.77 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells up to 72 hrs by MTT assay	[PMID: 28319780]
HCT-116	IC₅₀	2.4 μM Compound: 3	Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay	[PMID: 32273215]
HCT-116	IC₅₀	2.67 μM Compound: 3	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 32273215]
HCT-116	GI₅₀	3.5 μM Compound: 5	Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay Antiproliferative activity against human HCT116 cells after 48 hrs by sulforhodamine B assay	[PMID: 28716495]
HCT-116	IC₅₀	3.83 μM Compound: 3	Antiproliferative activity against human HCT116 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 24 hrs by MTT assay	[PMID: 32273215]
HCT-116	IC₅₀	34.7 μM Compound: Curcumin	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32731188]
HCT-116	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
HCT-116	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
HCT-116	IC₅₀	50 μM Compound: Curcumin	Antiproliferative activity against human HCT116 cells after 36 hrs by XTT assay Antiproliferative activity against human HCT116 cells after 36 hrs by XTT assay	[PMID: 29886021]
HEK293	IC₅₀	> 400 μM Compound: Curcumin	Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay Cytotoxicity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 26783179]
HEK293	CC₅₀	5.56 μM Compound: 1	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis Cytotoxicity against human HEK293 cells assessed as reduction in cell viability at 20 uM measured after 48 hrs by resazurin reagent based multilabel reader analysis	[PMID: 36608774]
HEK293	IC₅₀	7.7 μg/mL Compound: Curc	Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells preincubated for 16 hrs followed by TNFalpha addition and measured after 6 hrs by luminescence based assay Inhibition of TNFalpha-induced NFkappaB activation in human HEK293 cells preincubated for 16 hrs followed by TNFalpha addition and measured after 6 hrs by luminescence based assay	[PMID: 31767266]
HEK293	IC₅₀	94.1 μM Compound: Curcumin	Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
HEK-293T	IC₅₀	> 400 μM Compound: Curcumin	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 28797797]
HeLa	IC₅₀	12.11 μM Compound: 1a; Curcumin	Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
HeLa	IC₅₀	187 μM Compound: 4	Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay	[PMID: 26588603]
HeLa	IC₅₀	21.8 μM Compound: 1	Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs	[PMID: 26705144]
HeLa	IC₅₀	25.41 μM Compound: Curcumin	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28038323]
HeLa	IC₅₀	3.56 μM Compound: 3	Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 72 hrs by MTT assay	[PMID: 32273215]
HeLa	IC₅₀	3.57 μM Compound: 3	Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 48 hrs by MTT assay	[PMID: 32273215]
HeLa	IC₅₀	31.89 μM Compound: Curcumin	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HeLa	IC₅₀	32.4 μM Compound: 9	Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay Growth inhibition of human HeLa cells measured after 48 hrs by MTT assay	[PMID: 34669417]
HeLa	IC₅₀	5.39 μM Compound: 3	Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay	[PMID: 32273215]
HeLa	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
HeLa	IC₅₀	51.87 μM Compound: Curcumin	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 26873414]
HepG2	IC₅₀	10 μM Compound: Curcumin-I	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29798827]
HepG2	IC₅₀	13.78 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
HepG2	IC₅₀	16.01 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
HepG2	IC₅₀	17.3 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
HepG2	IC₅₀	17.37 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
HepG2	IC₅₀	20.3 μM Compound: 1; CUR	Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 Cells after 72 hrs by MTT assay	[PMID: 31129455]
HepG2	IC₅₀	27.23 μM Compound: 4	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
HepG2	IC₅₀	4.43 μM Compound: Curcumin	Cytotoxicity activity against human HepG2 cells by MTT assay Cytotoxicity activity against human HepG2 cells by MTT assay	[PMID: 26873414]
HepG2	IC₅₀	50 μM Compound: Curcumin	Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
HepG2	IC₅₀	52.3 μM Compound: curcumin	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 26894841]
HepG2	IC₅₀	72.7 μM Compound: 1a	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
HepG2	IC₅₀	9.44 μM Compound: 1; CUR	Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 Cells after 48 hrs by MTT assay	[PMID: 31129455]
Hs-578T	IC₅₀	55.45 μM Compound: Curcumin	Antiproliferative activity against human Hs578T cells after 24 hrs by MTT assay Antiproliferative activity against human Hs578T cells after 24 hrs by MTT assay	[PMID: 28319780]
HT-1080	IC₅₀	13.1 μM Compound: Curcumin	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 30138803]
HT-22	IC₅₀	52.4 μM Compound: 38	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of human HT-29 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay Growth inhibition of human HT-29 cells assessed as mitochondrial activity measured after 72 hrs by MTT assay	[PMID: 27521589]
HT-29	IC₅₀	> 25 μM Compound: 1a	Growth inhibition of human HT-29 cells measured after 72 hrs by SRB assay Growth inhibition of human HT-29 cells measured after 72 hrs by SRB assay	[PMID: 27521589]
HT-29	IC₅₀	14 μM Compound: Curc	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
HT-29	IC₅₀	20.73 μM Compound: CU	Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay Cytotoxicity against human HT-29 cells after 4 hrs by MTT assay	[PMID: 31336310]
HT-29	IC₅₀	23.4 μM Compound: 1; CUR	Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 Cells after 72 hrs by MTT assay	[PMID: 31129455]
HT-29	IC₅₀	51.7 μM Compound: 1a	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27843113]
Huh-7	IC₅₀	48 μM Compound: Curcumin	Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay Cytotoxicity against human HuH7 cells after 48 hrs by MTT assay	[PMID: 26783179]
Jurkat	IC₅₀	4.29 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay Antiproliferative activity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 24280069]
K562	GI₅₀	19.67 μM Compound: 1	Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay Inhibition of P-gp in doxorubicin resistant human K562 cells assessed as reduction in cell viability measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	GI₅₀	21.67 μM Compound: 1	Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay Antiproliferative activity against human K562 cells measured after 48 hrs by Presto blue assay	[PMID: 27908756]
K562	IC₅₀	23.12 μM Compound: Curcumin	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
K562	IC₅₀	36 μM Compound: 1; CUR	Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay Cytotoxicity against human K562 Cells after 24 to 48 hrs by MTT assay	[PMID: 31129455]
K562	IC₅₀	46.76 μM Compound: 4	Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
KBM5	IC₅₀	3.84 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay Antiproliferative activity against human KBM5 cells after 72 hrs by MTT assay	[PMID: 24280069]
KM12	IC₅₀	16 μM Compound: CU	Cytotoxicity against human KM12 cells after 4 hrs by MTT assay Cytotoxicity against human KM12 cells after 4 hrs by MTT assay	[PMID: 31336310]
L02	IC₅₀	22.69 μM Compound: Curcumin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
L02	IC₅₀	23.87 μM Compound: Curcumin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
L02	IC₅₀	25.67 μM Compound: Curcumin	Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
L02	IC₅₀	7.2 μM Compound: Curcumin	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
Lewis lung carcinoma cell line	IC₅₀	24.7 μM Compound: CUR	Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells measured after 72 hrs by MTT assay	[PMID: 27886548]
LN-229	IC₅₀	15 μM Compound: Curc	Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
LNCaP	IC₅₀	13.61 μM Compound: 1	Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against androgen-sensitive human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 30121214]
LNCaP	IC₅₀	13.61 μM Compound: Curcumin	Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human LNCAP cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
LNCaP	IC₅₀	13.61 μM Compound: 1	Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay	[PMID: 28388523]
LNCaP	IC₅₀	13.61 μM Compound: 1a; Curcumin	Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
LNCaP	IC₅₀	13.61 μM Compound: Curcumin	Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay Antiproliferative activity against human LNCAP cells after 3 days by WST or trypan blue assay	[PMID: 27543391]
LoVo	GI₅₀	4.3 μg/mL Compound: Curc	Growth inhibition of human LoVo cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability Growth inhibition of human LoVo cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability	[PMID: 31767266]
MCF7	IC₅₀	13.7 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32731188]
MCF7	IC₅₀	2.03 μM Compound: 3	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 32273215]
MCF7	IC₅₀	2.08 μM Compound: 3	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 32273215]
MCF7	IC₅₀	2.94 μM Compound: 3	Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay	[PMID: 32273215]
MCF7	IC₅₀	22.1 μM Compound: CUR	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
MCF7	IC₅₀	29.3 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition and measured after 72 hrs by SRB assay	[PMID: 34000484]
MCF7	IC₅₀	32.2 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 26174555]
MCF7	IC₅₀	41.9 μM Compound: 50	Anticancer activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay Anticancer activity against human MCF7 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36332549]
MCF7	IC₅₀	42.89 μM Compound: Curcumin	Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against ER/PR positive human MCF7 cells after 24 hrs by MTT assay	[PMID: 28319780]
MCF7	IC₅₀	46.25 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 26873414]
MCF7	IC₅₀	61.71 μM Compound: Curcumin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of resveratrol by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs in presence of resveratrol by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	68.25 μM Compound: Curcumin	Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by MTS assay	[PMID: 32485531]
MCF7	IC₅₀	68.25 μM Compound: 1; CUR	Cytotoxicity against human MCF7 Cells after 48 hrs by MTS assay Cytotoxicity against human MCF7 Cells after 48 hrs by MTS assay	[PMID: 31129455]
MCF7	IC₅₀	83.1 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
MCF7	IC₅₀	9.28 μM Compound: 1; CUR	Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 Cells after 48 hrs by MTT assay	[PMID: 31129455]
MCF7	IC₅₀	9.8 μM Compound: Curcumin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30138803]
MCF7R	IC₅₀	26.2 μM Compound: Curcumin	Cytotoxicity against human MCF7R cells assessed as cell growth inhibition and by MTT assay Cytotoxicity against human MCF7R cells assessed as cell growth inhibition and by MTT assay	[PMID: 34000484]
MDA-MB-157	IC₅₀	40.38 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-157 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDA-MB-231	IC₅₀	> 10 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29886021]
MDA-MB-231	IC₅₀	11.45 μM Compound: 1; CUR	Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 31129455]
MDA-MB-231	IC₅₀	12 μM Compound: Curc	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
MDA-MB-231	IC₅₀	15.81 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 28038323]
MDA-MB-231	IC₅₀	16.23 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells up to 72 hrs by MTT assay	[PMID: 28319780]
MDA-MB-231	IC₅₀	24.54 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 27816267]
MDA-MB-231	IC₅₀	31.39 μM Compound: 4	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
MDA-MB-231	IC₅₀	53.51 μM Compound: 50	Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36332549]
MDA-MB-231	IC₅₀	75.3 μM Compound: Curcumin	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
MDA-MB-453	IC₅₀	32.4 μM Compound: Curcumin	Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay Antiproliferative activity against HER2 positive human MDA-MB-453 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDA-MB-468	IC₅₀	42.89 μM Compound: Curcumin	Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDA-MB-468	IC₅₀	58.55 μM Compound: Curcumin	Antiproliferative activity against doxorubicin-resistant human MDA-MB-468 cells after 24 hrs by MTT assay Antiproliferative activity against doxorubicin-resistant human MDA-MB-468 cells after 24 hrs by MTT assay	[PMID: 28319780]
MDCK	CC₅₀	48.3 μM Compound: Curcumin	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as decrease in cell viability after 40 hrs by CellTiter-Glo assay	10.1039/C6MD00292G
MDCK	CC₅₀	48.3 μM Compound: Curcumin	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells assessed as reduction in cell viability after 40 hrs by CellTiter-Glo assay	[PMID: 30108865]
MGC-803	IC₅₀	> 20 μM Compound: 1; CUR	Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay Antiproliferative activity against human MGC803 cells after 24 hrs by MTT assay	[PMID: 31129455]
MGC-803	IC₅₀	31.39 μM Compound: CUR	Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human MGC803 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
N2a	IC₅₀	22.6 μM Compound: Curcumin	Neurotoxicity in mouse N2a cells assessed as cell viability for 24 hrs by MTT assay Neurotoxicity in mouse N2a cells assessed as cell viability for 24 hrs by MTT assay	[PMID: 34391121]
NCI-H1650	IC₅₀	20.5 μM Compound: Curcumin	Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H1650	IC₅₀	20.7 μM Compound: CUR	Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay Cytotoxicity against human NCI-H1650 cells measured after 72 hrs by MTT assay	[PMID: 27886548]
NCI-H1975	IC₅₀	1.4 μM Compound: Curcumin	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H460	IC₅₀	15 μM Compound: Curc	Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
NCI-H460	IC₅₀	17.11 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29429834]
NCI-H460	IC₅₀	17.14 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
NCI-H460	IC₅₀	20.3 μM Compound: Curcumin	Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human NCI-H460 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
NCI-H460	GI₅₀	27.3 μM Compound: 1	Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay Antiproliferative activity against human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	[PMID: 27908756]
NCI-H460	IC₅₀	5.3 μM Compound: 22	Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 32172081]
NCI-H460	IC₅₀	8.5 μM Compound: Curcumin	Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against human H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 29655083]
NCI-H460	IC₅₀	82.5 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human H460 cells after 24 hrs by MTT assay Cytotoxicity against human H460 cells after 24 hrs by MTT assay	[PMID: 26174555]
NHDF	IC₅₀	24.1 μM Compound: Curcumin	Cytotoxicity against NHDF after 72 hrs by MTT assay Cytotoxicity against NHDF after 72 hrs by MTT assay	[PMID: 30138803]
NIH3T3	IC₅₀	9.51 μM Compound: 1; CUR	Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 Cells after 48 hrs by MTT assay	[PMID: 31129455]
PANC-1	IC₅₀	53 μM Compound: Curc	Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
PC-12	CC₅₀	42 μM Compound: 1; CUR	Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay Cytotoxicity against rat PC12 cells measured after 24 hrs by WST8/PMS assay	[PMID: 31262559]
PC-12	CC₅₀	44 μM Compound: Curcumin	Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay Cytotoxicity against rat PC12 cells assessed as reduction in cell viability incubated for 24 hrs by WST-8 assay	[PMID: 33611188]
PC-3	IC₅₀	12.22 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28038323]
PC-3	GI₅₀	13.8 μg/mL Compound: Curc	Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay Growth inhibition of human PC3 cells incubated for 48 hrs by MTS assay	[PMID: 31767266]
PC-3	IC₅₀	18.65 μM Compound: Curcumin	Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 29429834]
PC-3	IC₅₀	18.71 μM Compound: Curcumin	Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 29174816]
PC-3	IC₅₀	18.8 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay Antiproliferative activity against human PC3 cells up to 72 hrs by MTT assay	[PMID: 28319780]
PC-3	IC₅₀	25.43 μM Compound: 1	Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against androgen-insensitive human PC3 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 30121214]
PC-3	IC₅₀	25.43 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human PC3 cells assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
PC-3	IC₅₀	25.43 μM Compound: 1	Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells after 3 days by WST-1 assay	[PMID: 28388523]
PC-3	IC₅₀	25.43 μM Compound: 1a; Curcumin	Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay Antiproliferative activity against human PC3 cells assessed as inhibition of cell viability after 3 days by WST-1 assay	[PMID: 26827161]
PC-3	IC₅₀	25.43 μM Compound: Curcumin	Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay Antiproliferative activity against human PC3 cells after 3 days by WST or trypan blue assay	[PMID: 27543391]
PC-3	IC₅₀	39 μM Compound: Curcumin	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27496212]
PWR-1E	IC₅₀	8.14 μM Compound: 1	Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay Antiproliferative activity against human PWR-1E cells after 3 days by WST-1 assay	[PMID: 28388523]
PWR-1E	IC₅₀	8.85 μM Compound: Curcumin	Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay Antiproliferative activity against human PWR-1E cells expressing androgen receptor and PSA assessed as decrease in cell viability after 3 days by WST assay	[PMID: 28601720]
QG-56	IC₅₀	100 μM Compound: Curcumin	Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human QG56 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 27318975]
QG-56	IC₅₀	100 μM Compound: Curcumin	Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay Cytotoxicity against human QG56 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26810315]
QGY-7703	IC₅₀	21.44 μM Compound: Curcumin	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
QGY-7703	IC₅₀	22.5 μM Compound: Curcumin	Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human QGY-7703 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
QGY-7703	IC₅₀	23.91 μM Compound: Curcumin	Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human QGY7703 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
RAW264.7	IC₅₀	> 100 μM Compound: Curcumin	Cytotoxicity against mouse RAW264.7 cells by MTT assay Cytotoxicity against mouse RAW264.7 cells by MTT assay	10.1039/C4MD00541D
RAW264.7	IC₅₀	0.8 μM Compound: Curcumin	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells measured after 20 hrs by griess assay	[PMID: 30108997]
RAW264.7	IC₅₀	1.89 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated with compound for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated with compound for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 35576655]
RAW264.7	IC₅₀	11.2 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha level preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by ELISA Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha level preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by ELISA	[PMID: 33422907]
RAW264.7	IC₅₀	12.3 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 1 hrs followed by LPS stimulation and measured after 24 hrs by Griess method	[PMID: 33422907]
RAW264.7	IC₅₀	14.7 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFN-gamma-stimulated nitric oxide production after 17 hrs by Griess assay	10.1039/C4MD00541D
RAW264.7	IC₅₀	15.95 μM Compound: Curcumin	Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay Inhibition of LPS/IFN-gamma-induced PGE2 production in mouse RAW264.7 cells after 17 to 20 hrs by enzyme immunoassay	[PMID: 27040659]
RAW264.7	IC₅₀	19.1 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 26841168]
RAW264.7	IC₅₀	2.2 μM Compound: Curcumin	Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW 264.7 cells assessed as inhibition of LPS-induced NO production measured after 24 hrs by Griess assay	[PMID: 35029398]
RAW264.7	IC₅₀	3 μM Compound: 1	Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs Inhibition of RANKL-induced osteoclastogenesis in murine RAW264.7 cells assessed as formation of TRAP positive multinucleated osteoclasts pretreated for 4 hrs followed by RANKL addition measured after 72 hrs	[PMID: 30794412]
RAW264.7	IC₅₀	3.5 μM Compound: Curcumin	Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 2 hrs followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 34726063]
SAOS-2	EC₅₀	28.1 μM Compound: Curcumin	Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human Saos2 cells expressing p53 mutant after 48 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
SAOS-2	EC₅₀	48.6 μM Compound: Curcumin	Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human Saos2 cells expressing p53 mutant after 24 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
Sf21	IC₅₀	25 μM Compound: Curcumin	Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co Inhibition of recombinant human full-length His6-tagged p300 expressed in baculovirus infected Sf21 insect cells using [3H]acetylCoA as substrate preincubated for 10 mins followed by substrate addition and measured after 10 mins by liquid scintillation co	[PMID: 31910017]
SGC-7901	IC₅₀	> 20 μM Compound: 1; CUR	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	[PMID: 31129455]
SGC-7901	IC₅₀	24.41 μM Compound: CUR	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
SGC-7901	IC₅₀	26.2 μM Compound: Curcumin	Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29288946]
SH-SY5Y	IC₅₀	16.1 μM Compound: 1	Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 48 hrs	[PMID: 26705144]
SH-SY5Y	EC₅₀	5.29 μM Compound: Curcumin	Neuroprotective activity against 6-OHDA induced cell death in human SH-SY5Y cells preincubated with 6-hyrdoxydopamine followed by compound addition and measured after 24 hrs by MTT assay Neuroprotective activity against 6-OHDA induced cell death in human SH-SY5Y cells preincubated with 6-hyrdoxydopamine followed by compound addition and measured after 24 hrs by MTT assay	[PMID: 35968659]
SH-SY5Y	EC₅₀	6.2 μM Compound: Curcumin	Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay	[PMID: 27420919]
SK-BR-3	IC₅₀	42.83 μM Compound: Curcumin	Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay Antiproliferative activity against HER2 positive human SKBR3 cells after 24 hrs by MTT assay	[PMID: 28319780]
SK-MEL-2	IC₅₀	36 μM Compound: Curc	Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
SK-OV-3	IC₅₀	43.63 μM Compound: 18, Curcumin, Diferuloylmethane	Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 24 hrs by MTT assay	[PMID: 26174555]
SK-OV-3	IC₅₀	49.85 μM Compound: Curcumin	Cytotoxicity against human SKOV3 cells by MTT assay Cytotoxicity against human SKOV3 cells by MTT assay	[PMID: 26873414]
SK-OV-3	IC₅₀	6.7 μM Compound: 1; CUR	Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay Cytotoxicity against human SKOV3 Cells after 48 hrs by Cell Titer Blue assay	[PMID: 31129455]
SMMC-7721	IC₅₀	12.57 μM Compound: 1; CUR	Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay Anticancer activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31129455]
SMMC-7721	IC₅₀	16.68 μM Compound: Curcumin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 30771605]
SMMC-7721	IC₅₀	18.8 μM Compound: Curcumin	Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against human SMMC-7721 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 34450496]
SMMC-7721	IC₅₀	19.47 μM Compound: Curcumin	Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29909338]
SW480	IC₅₀	10 μM Compound: Curcumin	Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric Inhibition of chymotrypsin-like activity of human 26S proteasome in human SW480 cells assessed as decrease in AMC hydrolysis using Suc-LLVY-AMC as substrate preincubated for 24 hrs followed by addition of substrate and measured after 2 hrs by fluorometric	[PMID: 30776692]
SW480	IC₅₀	15 μM Compound: 1; CUR	Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay Cytotoxicity against human SW480 Cells after 24 to 48 hrs by MTT assay	[PMID: 31129455]
SW480	IC₅₀	17.94 μM Compound: CU	Cytotoxicity against human SW480 cells after 4 hrs by MTT assay Cytotoxicity against human SW480 cells after 4 hrs by MTT assay	[PMID: 31336310]
SW-620	IC₅₀	12.52 μM Compound: CUR	Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTS assay	[PMID: 26318057]
SW-620	IC₅₀	14 μM Compound: Curcumin	Cytotoxicity against human SW620 cells after 72 hrs by MTT assay Cytotoxicity against human SW620 cells after 72 hrs by MTT assay	[PMID: 30138803]
T47D	IC₅₀	19 μM Compound: Curc	Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
T47D	IC₅₀	30 μM Compound: Curcumin	Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human T47D cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 27517806]
T47D	IC₅₀	47.91 μM Compound: Curcumin	Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay Antiproliferative activity against ER/PR positive human T47D cells after 24 hrs by MTT assay	[PMID: 28319780]
T98G	IC₅₀	10 μM Compound: curcumin	Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay Antiproliferative activity against human T98G cells after 24 hrs by EZ-Tox assay	[PMID: 26631318]
T98G	IC₅₀	25 μM Compound: curcumin	Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay Antiproliferative activity against human T98G cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26631318]
THP-1	IC₅₀	22.54 μM Compound: Curcumin	Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human THP1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 29421568]
U-251	IC₅₀	15.26 μM Compound: 1; CUR	Cytotoxicity against human U251MG cells after 48 hrs by MTS assay Cytotoxicity against human U251MG cells after 48 hrs by MTS assay	[PMID: 31129455]
U-251	IC₅₀	25.81 μM Compound: 4	Cytotoxicity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human U-251 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 34020339]
U-266	IC₅₀	7.57 μM Compound: 1, Curcumin, diferuloylmethane	Antiproliferative activity against human U266 cells after 72 hrs by MTT assay Antiproliferative activity against human U266 cells after 72 hrs by MTT assay	[PMID: 24280069]
U2OS	EC₅₀	22.8 μM Compound: Curcumin	Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human U2OS cells expressing wild-type p53 after 48 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
U2OS	EC₅₀	34.4 μM Compound: Curcumin	Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay Cytotoxicity against human U2OS cells expressing wild-type p53 after 24 hrs by crystal violet-staining based spectrophotometric assay	[PMID: 26606246]
U-373MG ATCC	IC₅₀	> 50 μM Compound: 1; CUR	Cytotoxicity against human U373MG Cells 48 hrs by MTS assay Cytotoxicity against human U373MG Cells 48 hrs by MTS assay	[PMID: 31129455]
U-87MG ATCC	IC₅₀	16 μM Compound: Curc	Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 28654265]
U-87MG ATCC	IC₅₀	18.4 μM Compound: Curcumin	Neurotoxicity in human U87 MG cells assessed as cell viability for 24 hrs by MTT assay Neurotoxicity in human U87 MG cells assessed as cell viability for 24 hrs by MTT assay	[PMID: 34391121]
U-87MG ATCC	IC₅₀	7.15 μM Compound: 1; CUR	Cytotoxicity against human U87MG Cells 48 hrs by MTS assay Cytotoxicity against human U87MG Cells 48 hrs by MTS assay	[PMID: 31129455]
U-937	IC₅₀	1.88 μM Compound: Curcumin	Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay Inhibition of LPS/IFN-gamma-induced PGE2 production in PMA-treated human U937 cells after 17 to 20 hrs by enzyme immunoassay	[PMID: 27040659]
Vero	IC₅₀	10.97 μM Compound: 3	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 32273215]
Vero	IC₅₀	17.87 μM Compound: 3	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 32273215]
Vero	IC₅₀	25 μM Compound: 3	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 32273215]
WiDr	IC₅₀	26.82 μM Compound: CU	Cytotoxicity against human WiDr cells after 4 hrs by MTT assay Cytotoxicity against human WiDr cells after 4 hrs by MTT assay	[PMID: 31336310]
WRL68	IC₅₀	27.8 μM Compound: CUR	Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
Y79	IC₅₀	30 μM Compound: Cur	Antiproliferative activity against human Y79 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human Y79 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 33310285]

體外研究
(In Vitro)

Curcumin exerts its chemopreventive effects partly through the activation of nuclear factor (erythroid-2 related) factor 2 (Nrf2) and its antioxidant and phase II detoxifying enzymes^[1]. Curcumin inhibits T47D cells growth, with IC₅₀s of 25, 19 and 17.5 μM for 24, 48 and 72 h MTT assays respectively. IC₅₀s of curcumin and silibinin mixture against T47D cells, are 17.5, 15, and 12 μM for 24, 48, and 72 h exposure times, respectively^[2]. Curcumin (2.5-80 μM) induces apoptotic cell death in AGS and HT-29 cell lines, and the IC₅₀ is 21.9±0.1, 40.7±0.5 μM, respectively, in both AGS and HT-29 cell lines. Curcumin-induced apoptosis requires caspase activities in AGS and HT-29 cells. Curcumin induces ER Ca²⁺ decline and mitochondrial Ca²⁺ overloading^[3]. Curcumin induces the G2/M cell cycle arrest of LNCaP and PC-3 cells in a dose dependent manner. Curcumin upregulates the protein level of NF-kappaB inhibitor IkappaBalpha and downregulates protein levels of c-Jun and AR^[5].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Curcumin (10 mg/kg, p.o.) significantly prevents decrease in the percentage of sucrose consumption, as compared to the CMS-exposed rats. Curcumin treatment results in significant prevention of increase in TNF-α and IL-6 levels in stressed rats^[4]. Curcumin decreases binding of p300/CREB-binding protein (CBP) at the brain-derived neurotrophic factor (BDNF) promoter at 20 mg/kg (i.p.), reduces binding of P300/CBP at the BDNF promoter at 40 mg/kg, and decreases binding all the four proteins of p300/CBP and H3K9ac/H4K5ac at the BDNF promoter at 60 mg/kg in chronic constriction injury (CCI) rats^[6].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

368.38

Formula

C₂₁H₂₀O₆

CAS 號(hào)

458-37-7

性狀

固體

顏色

Yellow to orange

中文名稱

姜黃素；酸性黃；姜黃色素

結(jié)構(gòu)分類

初始來(lái)源

微生物

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 100 mg/mL (271.46 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.7146 mL	13.5729 mL	27.1459 mL
5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM	0.2715 mL	1.3573 mL	2.7146 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (8.14 mM); 澄清溶液

此方案可獲得 ≥ 3 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 30.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 98.84%

選擇批次：

Data Sheet (631 KB) SDS (393 KB)

COA (281 KB) HNMR (154 KB) RP-HPLC (261 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Gao S, et al. Curcumin attenuates arsenic-induced hepatic injuries and oxidative stress in experimental mice through activation of Nrf2 pathway, promotion of arsenic methylation and urinary excretion. Food Chem Toxicol. 2013 Jul 18. pii: S0278-6915(13)004 [Content Brief]

[2]. Nasiri M, et al. Curcumin and Silibinin Inhibit Telomerase Expression in T47D Human Breast Cancer Cells. Asian Pac J Cancer Prev. 2013;14(6):3449-53. [Content Brief]

[3]. Cao A, et all. Curcumin induces apoptosis in human gastric carcinoma AGS cells and colon carcinoma HT-29 cells through mitochondrial dysfunction and endoplasmic reticulum stress. Apoptosis. 2013 Jul 24. [Epub ahead of print] [Content Brief]

[4]. Jiang H, et al. Antidepressant-like effects of curcumin in chronic mild stress of rats: Involvement of its anti-inflammatory action. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 20. pii: S0278-5846(13)00150-4. [Content Brief]

[5]. Guo H, et al. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor. Pharmazie. 2013 Jun;68(6):431-4. [Content Brief]

[6]. Zhu X, et al. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model. PLoS One. 2014 Mar 6;9(3):e91303. [Content Brief]

[7]. Balasubramanyam K, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004 Dec 3;279(49):51163-71. [Content Brief]

[8]. Jun Wan Shin, et al. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification. Biochem Pharmacol. 2020 Mar;173:113820. [Content Brief]

Cell Assay ^[2]	T47D breast cancer cell line is grown in RPMI 1640 supplemented with 10% FBS, 2 mg/mL sodium bicarbonate, 0.05 mg/mL penicillin G, 0.08 mg/mL streptomycin. Culture is maintained on plastic flask and incubated at 37°C in 5% CO₂. After growing sufficient amount of cells, cytotoxic effect of silibinin and curcumin is studied by 24, 48 and 72 h MTT assays in which 1000 cell/well are cultivated in a 96 well plate. After 24 h incubation in 37°C with humidified atmosphere containing 5% CO₂, the cells are treated with serial concentrations of curcumin (5, 10, 20, 30, 40, 50, 60, 80, 100 μM), silibinin (20, 40, 60, 80, 100, 120, 140, 180, 200 μM), and curcumin-silibinin mixture (each of them 5, 10, 20, 30, 40, 50, 60, 80, 100 μM) for 24, 48 and 72 h in the quadruplicate manner, in addition to cells with 200 μL culture medium containing 10% DMSO for control. After incubation, the medium of all wells of the plate are exchanged with fresh medium and the cells are leaved for 24 h in incubator. Then, medium of all wells are removed carefully and 50 μL of 2 mg/mL MTT dissolved in PBS is added to each wells and the plate is covered with aluminum foil and incubated for 4.5 h again. After removing content of the wells, 200 μL pure DMSO is added to the wells. Then, 25 μL Sorensen’s glycine buffer is added and immediately absorbance of each wells is read in 570 nm using EL×800 Microplate Absorbance Reader with reference wavelength of 630 nm. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]	Curcumin (10?mg/kg), freshly suspended in saline, is administrated by oral gavage once a day for 3?weeks. Forty rats are randomLy assigned to 4 groups (n=10/each group): group I receives saline and serves as control, group II receives curcumin, group III is exposed to CMS andreceive saline and group IV are subjected to CMS andreceive curcumin. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Gao S, et al. Curcumin attenuates arsenic-induced hepatic injuries and oxidative stress in experimental mice through activation of Nrf2 pathway, promotion of arsenic methylation and urinary excretion. Food Chem Toxicol. 2013 Jul 18. pii: S0278-6915(13)004 [Content Brief] [2]. Nasiri M, et al. Curcumin and Silibinin Inhibit Telomerase Expression in T47D Human Breast Cancer Cells. Asian Pac J Cancer Prev. 2013;14(6):3449-53. [Content Brief] [3]. Cao A, et all. Curcumin induces apoptosis in human gastric carcinoma AGS cells and colon carcinoma HT-29 cells through mitochondrial dysfunction and endoplasmic reticulum stress. Apoptosis. 2013 Jul 24. [Epub ahead of print] [Content Brief] [4]. Jiang H, et al. Antidepressant-like effects of curcumin in chronic mild stress of rats: Involvement of its anti-inflammatory action. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 20. pii: S0278-5846(13)00150-4. [Content Brief] [5]. Guo H, et al. Curcumin induces cell cycle arrest and apoptosis of prostate cancer cells by regulating the expression of IkappaBalpha, c-Jun and androgen receptor. Pharmazie. 2013 Jun;68(6):431-4. [Content Brief] [6]. Zhu X, et al. Curcumin alleviates neuropathic pain by inhibiting p300/CBP histone acetyltransferase activity-regulated expression of BDNF and cox-2 in a rat model. PLoS One. 2014 Mar 6;9(3):e91303. [Content Brief] [7]. Balasubramanyam K, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem. 2004 Dec 3;279(49):51163-71. [Content Brief] [8]. Jun Wan Shin, et al. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification. Biochem Pharmacol. 2020 Mar;173:113820. [Content Brief]

Curcumin 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7146 mL	13.5729 mL	27.1459 mL	67.8647 mL
	5 mM	0.5429 mL	2.7146 mL	5.4292 mL	13.5729 mL
	10 mM	0.2715 mL	1.3573 mL	2.7146 mL	6.7865 mL
	15 mM	0.1810 mL	0.9049 mL	1.8097 mL	4.5243 mL
	20 mM	0.1357 mL	0.6786 mL	1.3573 mL	3.3932 mL
	25 mM	0.1086 mL	0.5429 mL	1.0858 mL	2.7146 mL
	30 mM	0.0905 mL	0.4524 mL	0.9049 mL	2.2622 mL
	40 mM	0.0679 mL	0.3393 mL	0.6786 mL	1.6966 mL
	50 mM	0.0543 mL	0.2715 mL	0.5429 mL	1.3573 mL
	60 mM	0.0452 mL	0.2262 mL	0.4524 mL	1.1311 mL
	80 mM	0.0339 mL	0.1697 mL	0.3393 mL	0.8483 mL
	100 mM	0.0271 mL	0.1357 mL	0.2715 mL	0.6786 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門(mén)：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Curcumin (Synonyms: 姜黃素; Diferuloylmethane; Natural Yellow 3; Turmeric yellow)

Customer Review

Other Forms of Curcumin:

MCE 顧客使用本產(chǎn)品發(fā)表的 79 篇科研文獻(xiàn)

Curcumin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Histone Acetyltransferase 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Curcumin 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Curcumin (Synonyms: 姜黃素; Diferuloylmethane; Natural Yellow 3; Turmeric yellow)

Customer Review

Other Forms of Curcumin:

Curcumin 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 79 篇科研文獻(xiàn)

Curcumin 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Histone Acetyltransferase 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Curcumin 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Curcumin 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門(mén)區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z